Continue to Site

Eli Lilly is cutting the price of insulin by 70%

By Sean Whooley | March 1, 2023

Eli Lilly (NYSE:LLY) announced today that it plans to execute price reductions of 70% for its most commonly prescribed insulins.

Indianapolis-based Lilly also plans to expand its Insulin Value Program. This caps patient out-of-pocket costs at $35 or less per month.

The company said it took these actions to “help Americans” in a “complex healthcare system” that can keep them from receiving affordable insulin.

Get the full story at our sister site, Drug Delivery Business News.

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.